28 October 2024
Assura plc
Proposed secondary listing on the Johannesburg Stock Exchange
Assura plc ("Assura" or the "Company"), the
Assura believes that admission to trading of the shares on the JSE will be beneficial to the Company and its stakeholders. The Board of Assura believes that the secondary listing can be expected to contribute to liquidity in the Company's shares through its increased profile in the South African market.
The listing of Assura on the JSE is expected to become effective later this year, subject to the necessary regulatory approvals in
HSBC is acting as Listing Co-ordinator and Corporate Broker and Nedbank Corporate and Investment Banking, a division of Nedbank Limited, as JSE Sponsor.
Jonathan Murphy, CEO, said:
"We are excited to announce that we are moving forward with an application for a secondary listing on the Johannesburg Stock Exchange which we believe will contribute to liquidity in our shares.
"As the
- Ends -
For more information, please contact:
Assura plc |
Tel: 0161 515 2043 |
David Purcell, Investor Relations Director |
Email: Investor@assura.co.uk |
FGS Global Gordon Simpson Grace Whelan
|
Email: Assura@fgsglobal.com |
HSBC Bank Plc Chloe Ponsonby Jonathan Surr Louis Davies |
Tel: 020 7991 8888 |
Notes to Editors
Assura plc is the
A
At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real Estate Association
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.